NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shape Therapeutics

Shape Therapeutics

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://shapetx.com/

Last Round

Series B

Jul 15, 2021

Total Funding Raised

$147.5M

Company Overview

Shape Therapeutics is a biotechnology company that develops programmable RNA medicines to address genetic diseases using AI-driven RNA editing and gene therapy platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

RNA editinggene therapyadeno-associated virusAAVAI-driven drug discoveryprogrammable RNAgenetic medicinebiotech platformcapsid engineeringgenerative biologyRNA therapeuticsdrug discovery platformADARbiotech R&Din silico drug design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shape Therapeutics Comparables

Compare Shape Therapeutics with similar companies based on industry and business-model similarity.

Shape Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AIRNA
87%
Ascidian Therapeutics
84%
Amber
82%

Shape Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 15, 2021
Series ANov 5, 2019

Key People

Founding team and executive leadership

Adrian W Briggs

Chief Technology Officer, Interim Chief Executive Officer

Executive Team

Shape Therapeutics Investors

Notable investors and investment history

Shape Therapeutics investors
InvestorRounds
CureDuchenne VenturesSeries A
New Enterprise Associates (NEA)Series B, Series A
BioInnovation CapitalSeries B
Mission BioCapitalSeries B
Willett AdvisorsSeries B
Decheng CapitalSeries B
Breton Capital VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 16, 2025

    Collaborating with VectorY Therapeutics on vectorized antibody therapies for neurodegenerative diseases.

  • Jul 15, 2021

    $112M round led by Breton Capital Ventures and Decheng Capital.

Shape Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shape Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shape Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range31
Year Founded2018
Last FundingJul 15, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.